Millenia Hope Biopharma and Sederma sign contract

    WILMINGTON, DE, and MONTREAL, QC, Jan. 30 /CNW/ - Millenia Hope Inc.,
(OTC: BB MLHP - Frankfurt: MLF), is pleased to announce that, through Millenia
Hope Biopharma (MH-B), it has finalized a contract with Sederma S.A.S. of
France. Since 1964, Sederma has been devoted to the development of active
ingredients and the creation of innovative concepts for the cosmetic industry.
Conducting ongoing research and incorporating the latest scientific
advancements into the products they bring to the market, Sederma has a stake
in products that are plant derived.
    MH-B is a world leader in Phytomics Technology and is ideally suited
through its expertise, infrastructure, and library of phytochemicals to
deliver on natural product discovery and development.
    MH-B is extremely pleased to associate itself with a highly regarded
international organization such as Sederma and looks forward to future


    Millenia Hope develops innovative treatments and products that enhance
the quality of life, has put in place programs to fight major infectious
diseases, and promote healthier lives. Our team is committed to research and
development to deliver on global medical needs and to bring hope through
healthcare solutions.


    Millenia Hope Biopharma (MH-B) is one of the world's leading bioresearch
firms in Phytomic Technologies, commercializing plant-cell based bioprocesses
for the discovery, development and production of natural and novel
plant-derived products for the pharmaceutical, cosmetic and nutraceutical
industries. MH-B has spent over $30 million in developing its unique Phytomics
Technologies, including the world's largest library of highly purified
phytochemical fractions to be utilized by the pharmaceutical, cosmetic and
nutraceutical industry. MH-B is in the midst of the commercializing several
projects with leading multi-national corporations.


    Certain statements made in the release may contain language describing
the plans, goals, strategies, intentions, forecasts, and expectations of
Millenia Hope/Millenia Hope Biopharma that may be referred to as
"forward-looking statements." Several important factors could cause actual
results to differ materially from those in such forward-looking statements and
Millenia Hope could encounter unanticipated obstacles and delays in developing
products, services, and markets.

For further information:

For further information: Dr. Bahige Baroudy, (514) 846-5757, (514)

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890